Amgen Unrealized Gain (Loss) on Investments decreased by 107.3% to -$143.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 111.0%, from $1.30B to -$143.00M.
anet_unrealized_gain_loss_on_investments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q4 '22 | Q1 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | -$211.00M | -$111.00M | -$14.00M | $1.83B | $135.00M | $261.00M | -$515.00M | -$401.00M | $1.63B | -$876.00M | $1.30B | $1.97B | -$143.00M |
| QoQ Change | — | — | — | — | +47.4% | +87.4% | >999% | -92.6% | +93.3% | -297.3% | +22.1% | +507.2% | -153.6% | +247.8% | +52.2% | -107.3% |
| YoY Change | — | — | — | — | — | — | +967.3% | — | >999% | -128.1% | — | >999% | -435.6% | +351.5% | +20.7% | -111.0% |